Mikhail Blagosklonny and His Plans for Oncology


Mikhail Blagosklonny, researcher, professor, and philanthropist, has played a significant roll in the study of cancer and again. Mikhail Blagosklonny works as a professor of Oncology at the Roswell Park Cancer Institute in Buffalo, New York. He has headed up major research on the topic of cancer treatments. Mikhail Blagosklonny is also editor-in -Chief for Oncotarget where he has published the results of his extensive research about the natural process of aging.

Arguably, one of his more noteworthy accomplishments is his advocation for the use of Rapaymycin, a cancer drug, for the purpose of lengthening life of humans. This study has been a break through in this field of science, and remains unparalleled in its import to date.

Why all the fanfare regarding the use of Rapaymycin? One reason is because of the immunosupressant qualities of the drug. When an organ transplant occurs, there is danger of rejection of the new organ. If the rejection happens, the transplant fails. To help prevent this from happening, doctors typically prescribe anti-rejection drugs such as calcineurin inhibitors, or immunosuppressant drugs. The downside to the use of these drugs is that over time, they can actually damage the kidneys of the patient. Rapaymycin has a low level of toxicity on the kidneys, therefore reducing the chance of damage.

Another break-though application of the use of Rapaymycin is in the treatment of cancer. When fighting cancer, Sirolimus is commonly recommended because of its antiproliferative properties. Rapaymycin, in proper doses, is able to boost the immune response of the body against tumors. By the same token, tumor regression is also enhanced. By using Rapaymycin, the chances of contracting cancer in transplant patients are decreased.

As a researcher and professor in Oncology, Mikhail Blagosklonny is particularly interested in the connection between cancer and aging, and why cancer is more common in people above a certain age. His goal is not only to figure out the why of when cancer occurs, but also the logistics of treating cancer. He hopes to discover a method of treatment that is not as costly and painful as they are today. Mikhail Blogosklonny wants to find a way to destroy the cancer cells without damaging the healthy cells, which are vitally important in the process of recovery.

In the field of aging, Mikhail Blagosklonny continues with research regarding the effects of Rapaymycin on longevity. So far, the studies have shown that when Rapaymycin is administered before the flu vaccination that there is some immunological rejuvenation in elderly patients. Though the research is still in progress, Mikhail Blagosklonny is hopeful that the drug will lead to increasing a person’s longevity.

Topics that have inspired Mikhail Blagosklonny have attracted attention in the medical field. The progress made has generated interest from many others in his field around the world who will carry on the studies. Mikhail Blagosklonny believes that treatment for cancer will be developed. He also believes that the treatment will not be a luxury, but will be cost-effective and available to everyone.